Literature DB >> 2467568

Distribution of human leukocyte antigen-ABC and -D/DR antigens in the unfixed human testis.

G G Haas1, O J D'Cruz, L E De Bault.   

Abstract

The distribution of the major histocompatibility complex (MHC) antigens in the unfixed human testicle was studied by indirect immunofluorescence. Three murine monoclonal antibodies to the common determinants of class I MHC antigens (human leukocyte antigen [HLA]-ABC) and three against class II MHC antigens (HLA-D/DR antigens), respectively, were utilized. No class I MHC antigens were identified on developing testicular germ cells including spermatozoa, but interstitial cells between the seminiferous tubules (including Leydig cells) and blood vessel endothelium expressed the antigen. Class II MHC antigens were not found on any cells within the seminiferous tubules. However, the class II antigen was identified on dendritic-like cells between the seminiferous tubules and on vessel endothelium, although its expression was expectedly limited. These findings indicate that human testicular germ cells express minimal or no MHC antigens.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2467568     DOI: 10.1111/j.1600-0897.1988.tb00234.x

Source DB:  PubMed          Journal:  Am J Reprod Immunol Microbiol        ISSN: 8755-8920


  15 in total

1.  Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA-DR molecules.

Authors:  G Zeng; C E Touloukian; X Wang; N P Restifo; S A Rosenberg; R F Wang
Journal:  J Immunol       Date:  2000-07-15       Impact factor: 5.422

Review 2.  Tumour-associated antigens: considerations for their use in tumour immunotherapy.

Authors:  Adam J Linley; Murrium Ahmad; Robert C Rees
Journal:  Int J Hematol       Date:  2011-03-01       Impact factor: 2.490

Review 3.  Insights into the processing of MHC class I ligands gained from the study of human tumor epitopes.

Authors:  Nathalie Vigneron; Benoît J Van den Eynde
Journal:  Cell Mol Life Sci       Date:  2011-03-09       Impact factor: 9.261

4.  Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients.

Authors:  Julien Fourcade; Zhaojun Sun; Mourad Benallaoua; Philippe Guillaume; Immanuel F Luescher; Cindy Sander; John M Kirkwood; Vijay Kuchroo; Hassane M Zarour
Journal:  J Exp Med       Date:  2010-09-06       Impact factor: 14.307

5.  PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients.

Authors:  Julien Fourcade; Pavol Kudela; Zhaojun Sun; Hongmei Shen; Stephanie R Land; Diana Lenzner; Philippe Guillaume; Immanuel F Luescher; Cindy Sander; Soldano Ferrone; John M Kirkwood; Hassane M Zarour
Journal:  J Immunol       Date:  2009-05-01       Impact factor: 5.422

6.  Testisimmune privilege - Assumptions versus facts.

Authors:  G Kaur; P Mital; J M Dufour
Journal:  Anim Reprod       Date:  2013-01       Impact factor: 1.807

7.  Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes.

Authors:  P Chaux; V Vantomme; V Stroobant; K Thielemans; J Corthals; R Luiten; A M Eggermont; T Boon; P van der Bruggen
Journal:  J Exp Med       Date:  1999-03-01       Impact factor: 14.307

Review 8.  Human tumor antigens recognized by T lymphocytes.

Authors:  T Boon; P van der Bruggen
Journal:  J Exp Med       Date:  1996-03-01       Impact factor: 14.307

9.  Translation of a retained intron in tyrosinase-related protein (TRP) 2 mRNA generates a new cytotoxic T lymphocyte (CTL)-defined and shared human melanoma antigen not expressed in normal cells of the melanocytic lineage.

Authors:  R Lupetti; P Pisarra; A Verrecchia; C Farina; G Nicolini; A Anichini; C Bordignon; M Sensi; G Parmiani; C Traversari
Journal:  J Exp Med       Date:  1998-09-21       Impact factor: 14.307

10.  A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma.

Authors:  B Van den Eynde; O Peeters; O De Backer; B Gaugler; S Lucas; T Boon
Journal:  J Exp Med       Date:  1995-09-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.